Influenza A H1N1
7
0
0
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 7 trials
100.0%
+13.5% vs benchmark
14%
1 trials in Phase 3/4
33%
2 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (7)
Study of SAB-176 in Healthy Adult Participants
A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus
Exploring Safety & Clinical Benefit of Anti-Influenza Immunoglobulin Intravenous in Hospitalized Adults With Influenza A
Dose, Safety, and Pathogenicity of a New Influenza H1N1 Challenge Strain
Tomographic Findings in COVID-19 and Influenza H1N1
Kinetics of the Immune Response to Inactivated Influenza Vaccine in Healthy Adults
Observational Safety and Effectiveness Study of Adjuvanted Swine Origin A (H1N1) Pandemic Subunit Egg Derived Vaccine